The proper addition of shortcuts to a regular substrate can lead to the formation of a complex network with a highly efficient structure for navigation [J. M. Kleinberg, Nature 406, 845 (2000)]. Here we show that enhanced flow properties can also be observed in these small-world topologies. Precisely, our model is a network built from an underlying regular lattice over which long-range connections are randomly added according to the probability, Pij ∼ r−α ij , where rij is the Manhattan distance between nodes i and j, and the exponent α is a controlling parameter. The mean two-point global conductance of the system is computed by considering that each link has a local conductance given by gij ∝ r−C ij , where C determines the extent of the geographical limitations (costs) on the long-range connections. Our results show that the best flow conditions are obtained for C = 0 with α = 0, while for C ≫ 1 the overall conductance always increases with α. For C ≈ 1, α = d becomes the optimal exponent, where d is the topological dimension of the substrate. Interestingly, this exponent is identical to the one obtained for optimal navigation in small-world networks using decentralized algorithms.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1103/PhysRevLett.112.148701 | DOI Listing |
Front Biosci (Landmark Ed)
December 2024
Department of Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, 400016 Chongqing, China.
Background: Acute lung injury (ALI) significantly impacts the survival rates in intensive care units (ICU). Releasing a lot of pro-inflammatory mediators during the progression of the disease is a core feature of ALI, which may lead to uncontrolled inflammation and further damages the tissues and organs of patients. This study explores the potential therapeutic mechanisms of Dexmedetomidine (Dex) in ALI.
View Article and Find Full Text PDFOncol Res
December 2024
China-America Cancer Research Institute, Guangdong Medical University, Dongguan, 523808, China.
Background: Immune checkpoint inhibitors play an important role in the treatment of solid tumors, but the currently used immune checkpoint inhibitors targeting programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T-lymphocyte antigen-4 (CTLA-4) show limited clinical efficacy in many breast cancers. B7H3 has been widely reported as an immunosuppressive molecule, but its immunological function in breast cancer patients remains unclear.
Methods: We analyzed the expression of B7H3 in breast cancer samples using data from the Cancer Genome Atlas Program (TCGA) and the Gene Expression Omnibus (GEO) databases.
Oncol Res
December 2024
Department of General Surgery, Affiliated Hospital of Nantong University, Nantong, 226001, China.
Objective: Gastric cancer (GC) is a globally common cancer characterized by high incidence and mortality worldwide. Advances in the molecular understanding of GC provide promising targets for GC diagnosis and therapy. Long non-coding RNAs (lncRNAs) and their downstream regulators are regarded to be implicated in the progression of multiple types of malignancies.
View Article and Find Full Text PDFOncol Res
December 2024
Department of Respiratory Medicine, Shandong Provincial Third Hospital, Jinan, 250010, China.
Background: To investigate SCL/TAL 1 interrupting locus ()'s role and prognostic significance in lung adenocarcinoma (LUAD) progression, we examined and E2 promoter binding factor 1 (E2F1) expression and their impacts on LUAD prognosis using Gene Expression Profiling Interactive Analysis (GEPIA).
Methods: Functional assays including CCK-8, wound-healing, 5-ethynyl-2-deoxyuridine (EdU), Transwell assays, and flow cytometry, elucidated and E2F1's effects on cell viability, proliferation, apoptosis, and migration. Gene set enrichment analysis (GSEA) identified potential pathways, while metabolic assays assessed glucose metabolism.
Oncol Res
December 2024
Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Background: As a novel blocker of vascular endothelial growth factor receptor (VEGFR), fruquintinib has been approved for treating colorectal cancer (CRC). However, its dosage and therapeutic efficacy are limited by its widespread adverse reactions. Venetoclax, recognized as the initial inhibitor of B-cell lymphoma protein 2 (BCL2), has shown potential in boosting the effectiveness of immunotherapy against CRC.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!